AU2001231083A1 - Measuring cognitive impairment - Google Patents
Measuring cognitive impairmentInfo
- Publication number
- AU2001231083A1 AU2001231083A1 AU2001231083A AU3108301A AU2001231083A1 AU 2001231083 A1 AU2001231083 A1 AU 2001231083A1 AU 2001231083 A AU2001231083 A AU 2001231083A AU 3108301 A AU3108301 A AU 3108301A AU 2001231083 A1 AU2001231083 A1 AU 2001231083A1
- Authority
- AU
- Australia
- Prior art keywords
- user
- memory
- cognitive
- medical intervention
- responses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000010877 cognitive disease Diseases 0.000 title claims description 57
- 208000028698 Cognitive impairment Diseases 0.000 title claims description 23
- 230000004044 response Effects 0.000 claims description 160
- 238000012360 testing method Methods 0.000 claims description 150
- 230000015654 memory Effects 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 67
- 239000003814 drug Substances 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 20
- 238000004891 communication Methods 0.000 claims description 18
- 230000003920 cognitive function Effects 0.000 claims description 17
- 230000008859 change Effects 0.000 claims description 13
- 230000005855 radiation Effects 0.000 claims description 12
- 230000001149 cognitive effect Effects 0.000 claims description 11
- 208000010445 Chilblains Diseases 0.000 claims description 6
- 206010008528 Chillblains Diseases 0.000 claims description 6
- 230000005670 electromagnetic radiation Effects 0.000 claims description 5
- 238000001959 radiotherapy Methods 0.000 claims description 5
- 206010010904 Convulsion Diseases 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 206010001526 Air embolism Diseases 0.000 claims description 3
- 206010048962 Brain oedema Diseases 0.000 claims description 3
- 206010011951 Decompression Sickness Diseases 0.000 claims description 3
- 235000009300 Ehretia acuminata Nutrition 0.000 claims description 3
- 244000046038 Ehretia acuminata Species 0.000 claims description 3
- 206010073306 Exposure to radiation Diseases 0.000 claims description 3
- 208000001034 Frostbite Diseases 0.000 claims description 3
- 206010019332 Heat exhaustion Diseases 0.000 claims description 3
- 206010019345 Heat stroke Diseases 0.000 claims description 3
- 208000035202 High altitude pulmonary edema Diseases 0.000 claims description 3
- 208000034388 Mountain sickness acute Diseases 0.000 claims description 3
- 208000006079 Near drowning Diseases 0.000 claims description 3
- 208000018315 acute mountain sickness Diseases 0.000 claims description 3
- 208000008445 altitude sickness Diseases 0.000 claims description 3
- 208000006752 brain edema Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000001632 homeopathic effect Effects 0.000 claims description 3
- 230000002631 hypothermal effect Effects 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- 201000003152 motion sickness Diseases 0.000 claims description 3
- 230000000926 neurological effect Effects 0.000 claims description 3
- 238000009206 nuclear medicine Methods 0.000 claims description 3
- 210000000130 stem cell Anatomy 0.000 claims description 3
- 238000009210 therapy by ultrasound Methods 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 238000002591 computed tomography Methods 0.000 claims 4
- 230000007613 environmental effect Effects 0.000 claims 4
- 230000007170 pathology Effects 0.000 claims 4
- 230000003931 cognitive performance Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000000428 dust Substances 0.000 claims 2
- 210000003754 fetus Anatomy 0.000 claims 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229940124856 vaccine component Drugs 0.000 claims 2
- 238000012545 processing Methods 0.000 description 22
- 230000000007 visual effect Effects 0.000 description 21
- 230000035484 reaction time Effects 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 230000019771 cognition Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000002635 electroconvulsive therapy Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 2
- 206010010254 Concussion Diseases 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000009514 concussion Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 208000032484 Accidental exposure to product Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010056557 Gulf war syndrome Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 241001125831 Istiophoridae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 231100000818 accidental exposure Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 231100000573 exposure to toxins Toxicity 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 238000001503 one-tailed test Methods 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 201000010076 persian gulf syndrome Diseases 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Public Health (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Measuring Fluid Pressure (AREA)
- Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
Description
MEASURING COGNITIVE IMPAIRMENT
BACKGROUND
This application is a continuation-in-part of application serial no. 09/494475, filed on January 31, 2000.
A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever. Cognitive function can be impaired by physical insults such as radiation or chemical exposure. Measuring changes in cognitive function is thus an important way to quantify the adverse cognitive effects of such insults. Intentional exposure to electro-magnetic
radiation (including electricity) may cause cognitive impairment. For example, electro-convulsive therapy, used in psychiatric treatments, is acknowledged in the art to be beneficial to certain patients. It is, however, difficult to quantify how beneficial it is, as the cognitive impairment effects of ECT are difficult to measure. Similarly, radiation therapy (as, for example, for a cancer patient) is acknowledged to create memory loss. It is, however, difficult to measure this memory loss. Other electromagnetic exposure, such as exposure to laser light, or even excess exposure to sunlight, may impair cognition.
Similarly, accidental exposure to radiation may impair cognition. For example, it has been argued that cellular telephones, by exposing the user's brain to electromagnetic radiation, can impair cognition. The accuracy of this fear is, however, difficult to measure. Other types of physical intervention or therapy may affect cognition . For example, vaccine* , gene therapy and other kinds of biological implants (e . g. , transplants, stem cell implants and fetal cell implants ) , exposure to toxins, molds or chemicals in the environment ( including, for example, Gulf War
syndrome and other exposure to pollution or weapons chemical, nuclear, conventional or biological) , ingestion of vitamins, herbs, over the counter compositions or homeopathic preparations or other ingested things, may impair cognitive function, but measuring such effects until now has been prohibitively difficult.
There has thus been a need for a way to measure cognitive function more precisely, to quantify changes in cognitive function.
Published patents include the following: Steven J. Brown discloses a method for diagnosis and treatment of psychological and emotional disorders using a microprocessor based video game, United States Letters Patent No. 5,913,310. Disclosed examples include "schizophrenia, depression, hyperactivity, phobias, panic attacks, anxiety, overeating, and other psychological disorders" such as "personality disorders, obsessive-compulsive disorders, hysteria, and paranoia."
Joel S. Douglas et al. discloses an analyte testing system with test strips, United States Letters Patent No. 5,872,713. These test strips are effective to assay for certain chemical changes in a patient, but have not been used to assay cognitive dysfunction
or impairment.
Patrick Lichter discloses a personal computer card for collecting biological data, United States Letters Patent No. 5,827,179. The patent claims a portable computer card used with an air pressure transducer, see id. at claim 1, or a "biological data receiver," see id. at claim 6. The biological data receiver "can be adapted to receive biological data from a pulse oximetry sensor" or "from an ECG sensor." This system may be effective to assay for certain physical changes in a patient such as pulmonary function, but it has not been used to assay cognitive dysfunction or impairment.
Tom Marlin discloses a system for constructing formulae for processing medical data, United States Letters Patent No. 5,715,451. The patent says that rather than providing a prepared statistical analysis package, Marlin discloses a computer interface to construct statistical and other mathematical formulae to eaae he analysis of clinical data.
Stephen Raymond et al . discloses a health monitoring system that "tracks the state of health of a patient and compiles a chronological health history ... us[ing] a multipara etric monitor which ... automatically measures and records a plurality of
physiological data from sensors in contact with the patient's body," wherein "[t]he data collected is not specifically related to a particular medical condition" such as cognitive dysfunction. United States Letters Patent No. 5,778,882.
William Reber et al . discloses a medical communication timing system comprising an output device that generates an alert for the proper time to take a first medicine and a second medicine. United States Letters Patent No. 5,950,632 and United States Letters Patent No. 5,950,632.
Michael Swenson et al . discloses a virtual medical instrument for performing medical diagnostic testing, United States Letters Patent No. 5,623,925 and United States Letters Patent No. 5,776,057. The instrument "includes a universal interface having a number of electrical contacts and sets of electrical conduits associated with the different stored diagnostic test protocols. * * * The system is constructed to enable the selected diagnostic teat protocol to be performed on a patient after the corresponding set of electrical conduits are connected to the universal Interface contacts and to the patient. " Paul Tamburini* et al. discloses a diagnostic y
assay for Alzheimer's disease based on the proteolysis of the amyloid precursor protein, United States Letters Patent No. 5,981,208.
Not disclosed in the art - nor even suggested in it - is our non-invasive, computerized invention to accurately measure cognitive function and changes in cognitive function over time. There is a need for such an invention that is easy to administer, rapid, less expensive, and accurate enough to enable assessment of the cognitive impairment impact of a wide variety of agents or environments .
SUMMARY We have invented a solution that enables one to better assess the cognitive impairment impact of various physical insults. Our solution works at minimal cost per administration, compared to a roughly 55% to 65% accuracy and approximately $2,000 cost per assay for the personally administered assays previously known in the art.
Further, our assay shows consistent results regardless of the identity or experience level of the treating physician. Thus, the results obtained from our test can be pooled and compared among patients located in different study locations, with a level of
data comparability and accuracy not before available in the art. This data comparability greatly improves the usefulness and informative ness of the test responses. It improves the accuracy of the diagnosis of cognitive impairment in an individual patient. It enables clinical research done at different locations, and by different health care practitioners, to be easily compared. It improves the ability of research scientists to correctly evaluate the cognitive impact of a potential neurotoxin.
DETAILED DESCRIPTION Our invention entails using a computer to show a patient a series of cognitive dysfunction tests, receiving the patient's test responses, and analyzing these responses to assess cognitive dysfunction in the patient, whereby a conclusion regarding whether symptoms of cognitive dysfunction probably exist or are absent in the patient. Saliently, in contrast to the prior art, which teaches manual, one-time testing, our invention enables the comparison of multiple test results over time, to assess the change over time in a patient's responses. The patient's degree and rate of change over time is, in certain ways, significantly more informative that a static, one-time score.
1
The term "cognitive dysfunction testing protocol" connotes cognitive testing protocols to measure cognitive function (immediate and short-term memory and pattern recognition, for example) by providing the patient or user with a series of sensory stimuli, and measuring the user's ability to consciously and voluntarily respond to and remember said stimuli. To make our invention, one can use any of a wide variety of cognitive function testing protocols. Examples known in the art include the series of tests commercially available from The Psychological Corporation, a division of Harcourt Brace Jovanovich Publishers, New York, New York. The precise identity of the testing protocols is not important.
In our preferred embodiment, the cognitive dysfunction testing protocols are visual or auditory. That is to say, they entail showing the user a series of images or sounds and measuring the user's ability to remember and respond to these. We disclose and discuss below the specific details of some examples of cognitive dysfunction testing protocol.
Our invention is not, however, limited to these specific testing protocols disclosed below. One can readily make our invention using other visual
testing protocols. One can even make versions of our invention using other types of sensory response protocols. For example, one can make our invention using auditory stimuli, in place of visual stimuli. This may be necessary for assaying blind or visually-impaired users. This may also be preferred as advantageous to garner a more full picture of the patient's audio, visual, and even tactile responsiveness to cognitive testing protocols. As used herein, the term "Memory" denotes computer-readable memory on tangible media, able to store the test protocols, receive user responses, store a response evaluation protocol, and process said user responses according to said response evaluation protocol to generate a result (or "score") . In one version of our invention, the Memory is one single piece of electronic hardware, able to perform all of the required functions.
The Memory need not be one physical unit, however. In one preferred version, the Memory which receives the patient's responses into Memory which is physically located in an Internet-capable wireless phone, while the Memory which stores the most up-to-date version of the cognitive dysfunction testing protocol, and the software to perform the
complex user response evaluation, is in Memory physically located in an Internet accessible computer server. One of the advantages of our invention is that one can make it using an extremely wide variety of physical Memory configurations, as long as one provides Memory to perform each of the required functions .
As used herein, the term "computing apparatus" includes personal computer microprocessors for both stand alone computers and those connectable to an external network or software source such as the Internet. The term also includes any electronic hardware which can execute the neurological testing routine herein described. Thus, for example, our invention can be made using a personal handheld electronic organizer, such as the PALM PILOT (TM) , commercially available from Palm Computing, Inc., Santa Clara, California, a WINDOWS CE (TM) (Microsoft Corporation, Redmond, Washington) or wireless application protocol standard or blue tooth standard appliance, a wireless telephone with adequate memory, a wireless communications device connectable to an external software source (such as the Internet) , or a dedicated medical device whose sole function is to execute the cognitive testing
\o
protocols . Our invention can even be made using a television set, where the television is capable of receiving test responses from the subject, via a television remote-control device, for example. This is one of the advantages of our invention - it is extraordinarily flexible, and can be easily produced in an extremely wide variety of hardware. Our invention thus can be made in various versions which are durable, portable, inexpensive, etc..., as desired by a given kind of user.
As used herein, the term "Display" denotes apparatus to render the testing protocol perceivable by the user. In our preferred version, the display is the visual display screen on a portable personal computer (or PDA device) or on a wireless telephone. One can use other visual displays, however, including television screens or projector-based systems such as one finds for visual acuity testing at the optometrist's. Further, where one uses non-visual testing protocols, the Display will necessarily entail the ability to display the non-visual information. For example, if one uses sound auditory testing protocols, then the Display will need to include audio speakers or the like. As used herein, the term "Response Input"
//
denotes apparatus that the test user can use to input their responses to the test protocol into the Memory. In our preferred version, the Response Input is a keyboard or personal computer "mouse." However, one can use a stylus for a hand-held computing device, punch pads or a joystick, and so forth, or other types of electronic devices (e.g., wireless telephones, handheld computing devices, touch screen displays) and non-keyboard devices as appropriate. For example, one can use a television infrared remote-control unit, where the Display is a television. The Response Input can be anything able to communicate the user's responses to the Memory.
As used herein, the term "user response analysis software" is software capable of analyzing the user's responses to the cognitive dysfunction testing protocol, to assess whether symptoms of cognitive dysfunction likely exist or are absent in the user, based on the user's responses to the cognitive dysfunction testing protocol. The user response analysis software includes a computer readable data structure on computer readable, tangible media to store both patient responses, and the statistical analysis protocols that use the patient's responses as variable inputs. Such statistical
1 Z
analysis allows the most information to be obtained from these responses. Used appropriately, the statistical analysis enables the user to draw more sensitive, sophisticated conclusions from the user's responses. Statistical analysis capability had not before been combined in a single system with cognitive-function data (response) gathering capability, before the immediate invention. We disclose in detail below our preferred version of user response analysis software.
The term "Output" denotes a device capable of outputting the results of the user response analysis software. In our preferred embodiment, the Output includes two components: (a) a computer display screen, the same screen used as the "Display" to display the tests to the patient; and (b) a communications device to communicate the user's test results from the user response analysis software to a Memory for storage and later retrieval. Alternatively, one may use a printer, a modem
(including a wireless communication device) , a disk drive, or any other combination of hardware appropriate for the given version of our invention. For example, with a blind user, the Output may be an audio speaker.
The term "communication network" includes communication networks both open (such as a ground-line telephone, a radio, or a broadcast television network or the Internet) and closed (such as an intranet or a restricted access wide area network or local area network) .
As mentioned above, our invention is useful specifically to assess the effect on cognitive function of exposure to electromagnetic radiation, including accidental and intentional exposure. This includes nuclear medicine, excessive exposure to radiation including electric shock, sunlight, burns, heat stroke or heat exhaustion, and excess exposure to cold (frost-nip, frostbite, hypothermia, exposure, immersion, chilblains, pernio, etc.) .
One advantage of our invention, however, is that its application is not limited to any certain class of insult; rather, our invention can be used to inexpensively, easily and accurately assess the impact on cognitive dysfunction of any kind of physical insult. Thus, for example, our invention can be used to quantify the amount of cognitive impairment due to motion sickness, near drowning, decompression sickness (Caisson Disease and gas embolism) , high-altitude sickness (acute mountain sickness, high altitude
pulmonary edema, high altitude cerebral edema, Soroche, Puna, maroe, etc..) any kind of non-drug medical therapy, such as ultra-sound treatment, electro-convulsion therapy, radiation therapy, and tissue transplants.
In addition to quantifying the cognitive effects of physical insult, our invention is useful to quantify the cognitive effect of illness and other physical conditions. The best mode we currently know of also includes using our invention to evaluate the cognitive dysfunction impact (or side effect) of exposure to other physical insults, such as ambient radiation, cellular telephone radiation, or solar radiation. Cognitive Dysfunction Testing Protocols
A version of our invention particularly effective for evaluating cognitive effects entails doing a patient assessment at least once before the stimulus (e.g., exposure to the radiation), and at least once after exposure. This version entails having the patient take a series of cognitive dysfunction tests before the patient has been exposed, and receiving the patient's test responses, and analyzing these responses, to form a "baseline" performance level for the patient, and to also - after
the patient has been exposed - to have the patient take a series of cognitive dysfunction tests, and to receive the patient's test responses, and analyze these responses to form a new performance level for the patient, and to compare these new responses to the patient's earlier ("baseline") responses to then form a conclusion regarding whether syrr.ptoms of probable cognitive dysfunction exist.
In another version of our invention, the "baseline" is a composite of test results obtained by other, presumptively healthy people. Alternatively, the patient's insult-influenced results can be compared both to a standard "baseline, " and to the patient's personal results in the absence of the insult.
In the best mode we currently know of to practice our invention, one uses cognitive dysfunction testing protocols such as the following ones. These specific protocols are protected by copyright, ©2000 Head Minder, Inc. and ©2000 Panmedix, Inc.
Administration of the testing protocols is preceded by displaying an ethical statement on the privacy of the test results and a legal disclaimer. The testing protocols begin only after the user's identity is verified by a test administrator, or by
the user entering a code such as their social security number and a secret password. Before commencing the testing protocols, the user is informed that they should not take the tests if the user has recently used alcohol or other drugs capable of affecting cognitive ability.
Administration of the testing protocols is also preceded by gathering certain general information on the user. This information can be useful or necessary to best administer the tests and interpret the test results. This general information includes the patient's Name, the e-mail and street addresses and telephone numbers for the patient, the patient's physician, the local hospital, and the patient's legal guardian (if applicable), so that any of these can be contacted quickly in an emergency. In our preferred embodiment, the apparatus has a communications device such as wireless telephone capability or a modem. Similarly, we prefer to include contact information for the patient's health insurance provider, so that test information and results can be directly communicated to the insurer without intervening manual transcription. The patient's date of birth is, in our preferred embodiment, entered into the software and used to determine which version of certain testing
protocols to administer (we prefer to provide certain testing protocols in several different versions, each version suitable for a certain age group) . The Test Date can be entered automatically by the computing device if it has a timer/clock function. The patient's gender, sports played, dominant hand (right, left, ambidextrous) , and known prior history of type and date of prior seizures, concussions, reading problems, special education classes, native language, etc..., all can be used to adjust or interpret the testing protocol results. A chart of pupil sizes can be included, to allow the patient (or someone else) to quantify the patient's pupil size(s).
The identity and regime for the physical insult (e.g., electro-convulsive therapy, or radiation therapy) in questions can optionally be entered. This enables one to integrate with the result analysis software, a function to advise on the suggested future regime for the insult. If the testing protocol is supervised by someone other than the patient, we prefer to include an electronic "signature" to be entered by the test supervisor, to create a medical record authenticating who supervised the test. We prefer that the testing protocols
themselves be arranged or ordered to put at the very beginning those tests most indicative of the most severe cognitive impairment. This enables the software to rapidly triage patients and indicate, for patients with cognitive impairment which is severe, that medical intervention may be required immediately, without forcing the patient to complete each and every one of the testing protocols. Similarly, we prefer to order the testing protocols so that patients with superior cognitive function can, if desired, take a longer battery of assays, and obtain a statistically more accurate and precise measure of cognitive function.
At the beginning of the testing protocols, the user is shown the keyboard layout, and shown which keys are needed for responding. For each testing protocol, Screen Instructions are displayed on the Display, and the user must respond appropriately before the protocol begins. Each cognitive function testing protocol comprises a series of stimuli shown to the user, to which the user must respond. While it is possible to make testing protocols which use words, we prefer to use protocols which are based on images, not words. This minimizes the data bias based on less than
perfect literacy, using a nonnative language for the testing protocols, and the like.
Examples of cognitive function testing protocols include the following visual testing protocols :
Tracking Part I; Tracking Part II Incidental Learning Part I; Incidental Learning Part II; • Matching;
Response Direction Part I; Response Direction Part II; Response Inhibition; Memory Cabinet Learning; • Memory Cabinet Delayed Recall; Scanning Speed and Accuracy; Reaction Time; Cued Reaction Time; Visual Memory Part I; • Number sequencing;
Visual Memory Part II; and Number recall. These protocols are examples. Our preferred
embodiment uses many different specific test protocols. This makes it less likely that a user will memorize a specific test protocol and the perceived "correct" responses to it. We now more fully describe each these examples of testing protocols.
Tracking Part I Testing Protocol
At the beginning of this testing protocol, the Display displays the following Screen Instructions:
You are about to see a grid with 9 spaces, just like a tic-tac-toe board. A ball will appear in one of the nine spaces. A moment later, the ball will disappear. The ball will then reappear. If the ball appears in a different space, then do nothing. If the ball re-appears in the same space as the immediately preceding time, then press the SPACE BAR.
Press the SPACE BAR when you are ready to
begin.
The ball is displayed in a square for 1,500 milliseconds, followed by 500 milliseconds of all blank squares. If the ball appears in the same square two times in a row, the patient should press the space bar. The patient inputs their responses into the Response Input, and thus into the Memory, for further processing by the patient response analysis software. We prefer the testing protocol to present approximately thirty stimuli over about one minute. Tracking Part II Testing Protocol
At the beginning of this testing protocol, the Display displays the following Screen Instructions:
You are about to see the same grid as before. This time, press the SPACE BAR if the ball appears not in the space immediately preceding, but the space
"ZZ
before that one. The ball is displayed in the square for 1,500 milliseconds, followed by 500 milliseconds of blank squares. If the ball appears in the same square as the time before the previous time, the user should press the space bar. We prefer to display about sixty stimuli over about two minutes. The patient inputs their responses into the Response Input, and thus into the Memory, for further processing by the patient response analysis software. This test may be modified for patients with high cognitive functioning to require a response for the third preceding position, rather than the second or the immediately preceding one. Incidental Learning Part I
At the beginning of this testing protocol, the Display displays the following Screen Instructions:
Soon you will see a series of pictures appear on the screen. Whenever you see a picture of a plant (such as a fruit, tree or vegetable), press the space bar. If you see a picture of anything else, then do nothing. Try to be fast without making mistakes. You are being timed on how fast you respond.
Press the space bar when you are ready to begin. The Display then displays pictures of plants, animals, and everyday objects. Each picture is displayed for 2 seconds, followed by 1 seconds of blank screen. The patient inputs their responses into the Response Input, and thus into the Memory, for further processing by the patient response analysis software. We prefer to display about forty stimuli (about ten plants, 15 animals and 15 inanimate objects) over about two minutes .
Incidental Learning Part II
At the beginning of this testing protocol, the Display displays the following Screen Instructions:
Soon, you will see a series cf pictures. Some are from the series you saw a few minutes ago, while some are new. When you see a picture that you recognize from a. few moments ago, press the space bar. If you see a picture that you have not seen before, then do nothing. Try to be fast without making mistakes. You are being timed on how fast you are. Press the space bar when you are ready to begin.
The Display then displays pictures of plants, animals and everyday objects. About twenty images from the Incidental Learning Part I are repeated. Each picture is displayed for 2.0 seconds, followed by 1.0 second of blank screen. The patient inputs their responses into the Response Input, and thus into the Memory, for further processing by the patient response analysis software.
In our preferred embodiment, separate statistics for animate and inanimate picture responses are collected and compared. We prefer about forty stimuli over about two minutes. We prefer to give this test after Incidental Learning Part I and another, intervening task. Matching
At the beginning of this testing protocol, the Display displays the following Screen Instructions:
You are about to see, for ten seconds, ten matching pairs of shapes laid out in a grid. Study the shapes' locations. The shapes will then be hidden under small squares. Once the shapes are hidden, use your mouse to click on any square. The shape hidden beneath the square will appear. Then, use
your mouse to click on the square that you think covers the matching shape. If you do not find the matching shape, then both shapes will be covered again. Repeat the process until you find all the matching pairs . Try to make all the matches in as few tries as possible. You will not be timed. Press the space bar when you are ready to begin. The user must find ten matching pairs of shapes. All pairs are initially displayed for ten seconds, and then covered. In the example above, the Display displays one shapes. The user must then try to find the location of the other. The patient inputs their responses into the Response Input, and thus into the Memory, for further processing by the patient response analysis software. If the user is correct, both shapes in the pair stay uncovered. Otherwise, both will be covered up again. The test continues until all matches are made or until the user attempts forty guesses. There is no time limit.
Response Direction Part I At the beginning of this testing protocol,
the Display displays the following Screen Instructions:
Soon, you will see numbers appear briefly on the screen. Place your left index finger on the 1 key and your right index finger on the 0 key. When you see the number "1" displayed on your screen, press number 1 on your keyboard. When you see the number "0" displayed on your screen, press number 0 on your keyboard. If you see any other number, do nothing. Try to be fast without making mistakes. You are being timed on how fast you respond. Press the spacebar when you are ready to begin. The Display then displays a number for about 0.5 seconds, followed by 1.5 seconds of blank screen. The patient inputs their responses into the Response Input, and thus into the Memory, for further processing by the patient response analysis software. Responses can occur anytime before the next digit is displayed. We prefer displaying about sixty stimuli over about two minutes.
Response Direction Part II At the beginning- of this testing protocol, 7
the Display displays the following Screen Instructions:
Soon, you will see numbers appear briefly on the screen. Place your left index finger on the 1 key and your right index finger on the 0 key. Do the inverse of what you did on the last test. That is, when you see the number "1" displayed on your screen, press number 0 on your keyboard. When you see the number "0" displayed on your screen, press number 1 on your keyboard. If you see any other number, do nothing. Try to be fast without making mistakes. You are being timed on how fast you respond. Press the spacebar when you are ready to begin.
The Display then displays a number for about 0.5 seconds, followed by 1.5 seconds of blank screen. Responses can occur anytime before the next digit is displayed. The patient inputs their responses into the Response Input, and thus into the Memory, for further processing by the patient response analysis software. We prefer displaying about sixty stimuli over about two minutes.
Response Inhibition At the beginning of this testing protocol,
Z
the Display displays the following Screen Instructions:
Shortly, you will see a series of pictures. Press the space bar every time you see a picture except if it is of an animal. Press the spacebar as fast as you can. You are being timed. Remember, press the space bar every time you see a picture except if it is an animal. Press the space bar when you are ready to begin.
The Display then displays pictures of objects, plants, and animals. Each picture is displayed for 2.0 seconds, followed by 1.0 seconds of blank screen. The patient inputs their responses into the Response Input, and thus into the Memory, for further processing by the patient response analysis software. We prefer to use about sixty five stimuli over about 3.3 minutes.
Memory Cabinet Learning At the beginning of this testing protocol, the Display displays the following Screen Instructions :
In a moment, you will see a cabinet with nine common objects placed on different shelves. You will have twenty seconds to
memorize where each object is stored. Study hard. Doors will then close to cover the objects and you will be asked to find them, one at a time. You can do this by either (A) pressing the number key (1-9) on your keyboard that is the same as the door where you think the object is hidden, or (B) pointing and clicking your computer's mouse on the door where you think the object is hidden. If you make a mistake, then the test will remind you where the object is, so that you can find it later. You will be asked to find each object a total of four times. Press the space bar when you are ready to begin.
The user must memorize the locations of nine common objects. In one version, we prefer to use toys as objects. The locations are randomly generated for each user, to minimize users being able to "memorize" the locations. The user is queried about the locations one at a time. The patient inputs their responses into the Response Input, and thus into the Memory, for further processing by the patient response analysis software. After one round (9 queries), there is a second 10 second display, and then the process
3θ
repeats. This continues until the user has been asked for a location of each object four times. If the user guesses incorrectly, then the correct location is briefly shown. If he guesses correctly, the Display displays "correct." Statistics are collected for each round. There is no time limit.
Memory Cabinet Delayed Recall
At the beginning of this testing protocol, the Display displays the following Screen Instructions:
A few moments ago, you saw a cabinet with nine objects placed on different shelves. In a moment, you will be asked to find those items one at a time, just like you did before. This time, you will not see the objects first, and you will not be told if you are right or wrong. Press the spacebar when you are ready to begin. There is no initial display of objects. The user must recall their locations from Memory Cabinet Learning.
The patient inputs their responses into the Response Input, and thus into the Memory, for further processing by the patient response analysis software. There is only one round of queries, and no feedback about the correctness of a response. This test must
3/
be given after Memory Cabinet Learning, and preferably after another intervening task. Scanning Speed and Accuracy
At the beginning of this testing protocol, the Display displays the following Screen Instructions:
Now, look at the sample shapes below. The shapes are in two groups. If both the shapes on the left hand side of the line are also on the right hand side of the line, press the space bar ONCE. If the shapes are not BOTH on the right hand side, then press the space bar TWICE. You only get one chance for each item. Remember - press ONCE for yes and TWICE for no. Work as fast as you can without making any mistakes. Press the space bar when you are ready to begin. The Display then displays to the patient two groupings of symbols, one on the left side of the Display and
one grouping on the right side of the Display, like this:
<L A § ! S ? § <L A A
Each of approximately thirty groupings of symbols appears separately. The patient inputs their responses into the Response Input, and thus into the Memory, for further processing by the patient response analysis software. We prefer to fix the time required at ninety seconds.
An alternate version of this testing protocol is to ask the patient to hit the number "1" key if one target shape is present on the right side of the Display, and the number "2" key if both target shapes are present there. Reaction Time
At the beginning of this testing protocol, the Display displays the following Screen Instructions:
Look at the sample white circle below. Each time that you see the white circle, press the space bar. Try and be quick without making mistakes. Press the space bar when you are ready. The Display then displays a series of pictures to the patient, using a ratio of 1 "target" image (in this example, a white circle) for every several non-target images (in this example, nonwhite circles) displayed.
The patient inputs their responses into the
Response Input, and thus into the Memory, for further processing by the patient response analysis software. In our preferred version, in the Reaction Time testing protocol, the visual stimulus duration is 1.5 seconds, followed by 0.5 seconds of blank screen. The patient's response can therefore occur any time within the 1.5 second stimulus, but is not allowed thereafter.
For the personal computer versions of our inventions (in contrast to, for example, the PALM PILOT (TM) based versions), we prefer using certain software operating systems most able to accommodate the rapid response time limits of this testing protocol . Personal computer timers operate independently of the microprocessor speed. Thus, using a 266 MHz microprocessor, or a 450 MHz one, does not affect timer speed. However, different operating systems have different rates of updating the timer. Thus, on WINDOWS 3.11 (TM) , WINDOWS 95 (TM) and WINDOWS 98 (TM) (each commercially available from Microsoft Corp., Redmond, Washington), the timer is updated only 18.2 times per second, resulting in a maximum resolution of +27 milliseconds. For many testing protocols, this will have no significant impact.
Cued Reaction Time
At the beginning of this testing protocol, the Display displays the following Screen Instructions: Press the space bar only when the white circle is displayed after a black square is displayed. Do not press the space bar if the white circle is displayed after any other shape, nor any other color of square. Remember, press the space bar only when the white circles is displayed after a black square. Try and be quick without making mistakes. Press the space bar when you are ready to start. The Display then displays the black square followed by white circle pair, in a ratio of 1:6 with total other stimuli. The ratio of the target (white circle) with target primer (black square) , to target without a target primer, is 2:1. The patient inputs their responses into the Response Input, and thus into the Memory, for further processing by the patient response analysis software. This portion of the testing protocol takes 3 minutes.
Visual Memory Part I
At the beginning of this testing protocol, the Display displays the following Screen
Instructions:
Now, you will see a series of pictures appear on the display. Sometimes, you will see a picture a second time. Each time you see a picture for the second time, press the space bar. Press the space bar when you are ready to begin.
The Display then displays a series of pictures, as fo. example:
* J ® * ♦ 0 •
Each of the single forty pictures is displayed for two seconds. Of the forty pictures, twenty are repeated and twenty are not, for a test time of two minutes. The patient inputs their responses into the Response Input, and thus into the Memory, for further processing by the patient response analysis software. Number Seguencing
At the beginning of this testing protocol, the Display displays the following Screen Instructions:
Below is a key that pairs the numbers 1 through 9 with symbols. Beneath the key, you will see a aeries of symbols with empty boxes underneath. Fill in the correct
numbers for each symbol using the numeric keypad. If you make a mistake, just keep going. Try and fill in as many numbers as you can. Press the space bar once to begin.
The Display then displays, for ninety seconds, a screen like this:
KEY
TEST
The patient inputs their responses into the Response Input, and thus into the Memory, for further processing by the patient response analysis software. In our preferred embodiment, we use animal silhouettes rather than typographic symbols, but words, numbers, and any other visual indicia are all acceptable. Visual Memory Part II
At the beginning of this testing protocol, the Display displays the following Screen
Instructions:
Just a few moments ago, you saw a list of pictures. Some you saw once, others twice. Press the space bar when you see a picture that you recognize from before. It can be one that you just saw once, or one that you saw twice. Press the space bar when you are ready to begin. The Display then displays a series of pictures, one every two seconds. All the forty pictures from the Visual Memory Part II testing protocol are displayed, in addition to twenty new pictures, over a two minute total time. The patient inputs their responses into the Response Input, and thus into the Memory, for further processing by the patient response analysis software.
Number Recall
At the beginning of this testing protocol, the Display displays the following Screen Instructions :
Now, you will see a series of numbers appear on the display, followed by a display screen with some blanks on it. Using the number keys, enter the numbers in the blanks in exactly the same order as you see them. You
can use the backspace key to change your answer if you think you have made a mistake.
Press the space bar when you are ready to begin. The Display then displays a series of individual numerals, one numeral at a time, like this:
Each group of numerals is displayed for 750 milliseconds. The first groups displayed consist of only two numerals. Latter groups consist of longer and longer groups of numerals:
7 4 8 2 9
The patient inputs their responses into the Response Input, and thus into the Memory, for further processing by the patient response analysis software. The testing protocol continues until the patient makes two consecutive errors on the same level of difficulty (i.e., two consecutive errors with numeral groups having the same quantity of numerals in them) . When the patient makes these two consecutive errors, the testing protocol stops. Number sequencing
At the beginning of this testing protocol, the Display displays the following Screen
3?
Instructions:
Now, you will see a group of numerals appear on the display, followed by a display screen with some blanks on it. Using the numeric keypad, enter the numbers in the blanks in ASCENDING order. That is, order them from lowest to highest. You can use the backspace key to change your answer if you think you have made a mistake. Press the space bar when you are ready to begin.
The Display then displays a group of numbers, like this :
The patient inputs their response (the correct response would be "3 4 5" in the immediate example) into the Memory. Each group of numbers is presented for two seconds. The first groups displayed consist
of only three numerals . Latter groups consist of longer and longer groups of numerals:
2 8 3 1 9
The patient inputs their responses into the Response
Input, and thus into the Memory, for further processing by the patient response analysis software. The testing protocol is discontinued when the patient makes two consecutive errors on the same level of difficulty (i.e., with two consecutive number groups having the same quantity of numbers in them) . This test portion takes approximately three minutes. Summary
On completion of the testing protocol (s), the patient is informed that the testing is complete. Either after completion of all protocols, or during the test process, the patient's response data is used as variable inputs in the patient response analysis software.
Patient Response Analysis Software
The user's results for the cognitive dysfunction testing protocols are then analyzed statistically, to obtain the most information from them. In our invention, the statistical analysis capability is integrated into the system. This is done by incorporating directly into our system, patient response analysis software. The patient response analysis software uses as variable inputs the testing protocol results discussed above. The patient
response analysis software then statistically analyzes these responses and calculates certain values for each specific testing protocol, the values for certain protocols combined, and the values for all the protocols combined. We discuss each in turn. In our preferred version, we use the following statistical analysis protocols. This compilation 'of these statistical protocols is protected by copyright, ©2000 PanMedix, Inc. Individual Testing Protocols
For each separate cognitive dysfunction testing protocol, the patient response analysis software calculates: t = Average Response Time y = correct responses
0 = Errors of Omission (misses or errors)
C = Errors of Commission (false positives, if applicable)
From these, the following ratios can be derived: Proficiency Index = (0 + C) / t
Discriminabilitv = 100 x [1 - (0 + C / Number of Stimuli) ]
Note that in our preferred embodiment, neither Proficiency Index nor Discriminability are used.
Response Bias = (C - 0) / (C + 0) ; if no errors then = 0. Response Variability = mean standard deviation of response times. Response Variability is calculated for the continuous performance test protocol (s) (e.g., the "Go No-Go Test" above) only. 0 Level = y - C - O
Retention Index = 100 x Delayed Recall / Immediate Recall . Retention Index is calculated for the memory tests only. Test - Retest Correlation
If baseline data is available (either from a patient pool, or specifically from a prior test administered to that patient) , then the patient response analysis software can also calculate, for each of the above values, the correlation between a given baseline test value ("a") and the value obtained in a subsequent test ("b") . We denote this correlation here as "r(ab)." r(ab) = S(ab) / sqrt [S(aa) x S (bb) ]
S = Sigma = standard deviation
Mu = mean
S(aa) = SUM [(a - mean (a)) Λ 2]
S(bb) = SUM [ (b - mean (b) ) Λ 2] S(ab) = SUM [ab≤[(a - mean (a)) x (b - mean (b) ) ] ]
Selectively Combined Testing Protocol Analysis In addition to analyzing data for each testing protocol separately, the patient response analysis software combines the results of certain testing protocols for certain analyses.
General Attention = total correct responses for Number sequencing and Number recall protocols. Attention Consistency = the weighted number of digits in Number sequencing and Number recall. Attention Accuracy = (Discriminability for Response Speed + Discriminability for Response Cueing and Inhibition) / 2.
Attention Efficiency = (Proficiency for Response Speed + Proficiency for Response Cueing and Inhibition) / 2.
Processing Speed Accuracy = (Q Level for Symbol Scanning + Q Level for Number sequencing) / 2. Processing Speed Efficiency = (Proficiency for
Symbol Scanning + Proficiency for Number sequencing) / 2.
Memory Accuracy = (y for Visual Memory Part I + y for Visual Memory Part II) / 2. Memory Efficiency = (Proficiency for Visual
Memory Part I + Proficiency for Visual Memory Part II) / 2.
Reaction Time Index = average reaction time for Response Speed + average reaction time for Response Cueing and Inhibition.
Processing Speed Index = average reaction time for Symbol Scanning + average reaction time for Number sequencing.
Complex Reaction Time = average reaction time for Visual Memory Part II + average reaction time for Response Cueing and Inhibition. Total Combined Testing Protocol Values For all cognitive dysfunction testing protocols combined, the patient response analysis software calculates:
Overall Speed
Overall Accuracy
Overall Proficiency « Overall Speed / Overall
Accuracy
In our preferred embodiment, the speed, accuracy and efficiency result indices are generated at the domain level; that is to say, if one cognitive dysfunction testing protocol at baseline is outside the normal range, the software can still generate a statistically meaningful score. If this is not done, then if a patient does not understand the instructions, or has attention deficit disorder, or is disturbed by a telephone call during the test, then that patient's erroneous results will create systematic error which can distort the general score. Reliable Change Index
The patient response analysis software then calculates a "reliable change index." The reliable change index describes the change from the baseline value, which change is statistically reliable. There are many ways known in the art of statistics to calculate reliable changes. We prefer to calculate the reliable change index (or "RCI") as follows: RCI - X(b) - X(a) / s(d)
X(a) - the baseline value
X(b) = the immediate value s (d) = the standard difference for the sub test calculation, as calculated above. p = the probability of error &
Regardless of the specific statistical method used to calculate the RCI, the RCI threshold values should, optimally, be set considering generally accepted statistical principles. One tailed and other tests are possible. In our preferred version, the positive and negative RCI threshold values are derived from accepted medical neurology standards. Examples are given in Hinton-Bayre, A.D., " Concussion in Contact Sports : Reliable Change Indices of Impairment and Recovery, " Journal of Clinical and Experimental
Neuropsvchology, v.21, pp.70-86 (1999) . Other values may, however, be used.
For a one tailed test, we prefer to use a negative RCI threshold value of -1.65, with p < 0.05. We similarly prefer to use a positive RCI threshold value of -1.04 with p < 0.15. Using these amounts, a test result with an RCI < -1.65, indicates symptoms of cognitive dysfunction likely exist in the patient. By contrast, an RCI > -1.04 indicates symptoms of cognitive dysfunction likely do not exist in the patient. Other threshold values may, of course, be used.
If an RCI value falls outside its negative RCI threshold range, or if there is at least one active cognitive dysfunction symptom in the
ΎT
pre-testing protocol user survey, then the user response analysis software indicates that symptoms of cognitive dysfunction likely exist in the user. Conversely, if all RCI values are within the positive RCI threshold ranges and if there is no active trauma symptom, then the user response analysis software indicates that symptoms cf cognitive dysfunction likely do not exist in the user. If at least one RCI value falls inside the negative RCI threshold range but outside the positive RCI threshold range, and if there is no active trauma symptom, then the user response analysis software indicates that symptoms of cognitive dysfunction may exist in the user.
For certain applications (clinical trials, for example) , patients can establish a "baseline" score and use this baseline to compare to later scores. In such a use, RCI scores which fall too far outside the normal range (we prefer less than two standard deviations from the mean) are rejected, as cognitive impairment, even severe, may not statistically lower a score which is already quite low. Thus, we prefer to not have such users (nor their physicians) rely on these scores. Low baseline scores could be due to a number of factors including a history of learning problems, distraction and
4θ
confusion over the instructions, and a conscious attempt to fake a lowered score, in order to manipulate future results.
SUMMARY
Although the present invention has been described in considerable detail with reference to certain preferred versions, other versions are possible. Therefore, the spirit and scope of the appended claims should not be limited to only the description of our preferred versions contained in the foregoing discussion. The features disclosed in this specification, and the accompanying claims and abstract, may be replaced by alternative features serving the same equivalent or similar purpose, unless expressly stated otherwise. Thus, unless expressly stated otherwise, each feature disclosed is one example only of a generic series of equivalent or similar features. As used in £he claims appended, the word "a" includes the singular as well as the plural. The phrase "in communication with" entails both direct communication and indirect communication via one or more intermediary pieces (e.g., microprocessors, cables, etc.).
Y?
Claims (62)
1. A method for using computer readable, tangible Memory to evaluate the cognitive performance of a person, said method comprising: a. providing Testing Memory on computer readable, tangible media, said Testing Memory storing cognitive dysfunction testing protocols, b. providing Response Memory on computer readable, tangible media, said Response Memory able to receive and store user responses to said neurological pathology testing protocols, and c. providing Statistical Memory on computer readable, tangible media, said Statistical Memory storing user response analysis software.
2. The method of claim 1: said Response Memory comprising a "baseline" which is not the results of said user, whereby said user response analysis software can compare (i) the cognitive function testing protocol results for said user to (ii) said baseline result.
3. The method of claim 1: said Response Memory comprising said user's cognitive pathology testing protocol results taken on at least two different times, and
SO wherein said user response analysis software can compare said results.
4. The method of claim 3: wherein said data structure comprises responses for said user taken on at least two different times, whereby said user response analysis software can thereby compare for said user, responses of said user at a plurality of times.
5. The method of claim 4: wherein said user response analysis software calculates a reliable change index.
6. The method of claim 5: wherein said Memory is communicable to a communications device, whereby said user's cognitive dysfunction testing protocol responses may be communicated over said communication network.
7. The method of claim 6: wherein said communication network consists essentially of the Internet.
8. The method of claim 7 : wherein said communication network consists essentially of a wireless telephone network.
9. The method of claim 5 : used to quantify the cognitive impairment associated with motion sickness.
10. The method of claim 5: used to quantify the cognitive impairment associated with an insult selected from the group consisting of near drowning, decompression sickness (e.g., Caisson Disease, gas embolism) and high-altitude sickness (e.g. , acute mountain sickness, high altitude pulmonary edema, high altitude cerebral edema, Soroche, Puna, maroe) .
11. The method of claim 5: used to quantify the cognitive impairment associated with non-drug medical intervention.
12. The method of claim 11: wherein said non-drug medical intervention comprises ultra-sound treatment.
13. The method of claim 11: wherein said non-drug medical intervention comprises electro-convulsion therapy.
14. The method of claim 11: wherein said non-drug medical intervention comprises radiation therapy.
15. The method of claim 11: wherein said non-drug medical intervention comprises tissue transplant.
16. The method of claim 15: z wherein said tissue comprises stem cells.
17. The method of claim 15: wherein said tissue comprises at least part of an anatomical organ.
18. The method of claim 15: wherein said tissue comprises fetal tissue.
19. The method of claim 15: wherein said tissue consists essentially of genetic material.
20. The method of claim 11: wherein said non-drug medical intervention comprises nuclear medicine.
21. The method of claim 11: wherein said non-drug medical intervention comprises at least one medical scan (e.g., CT scan, Magnetic Resonance Imaging and CAT scan) .
22. The method of claim 11: wherein said non-drug medical intervention comprises at least one vaccine component.
23. The method of claim 11: wherein said non-drug medical intervention is selected from the group consisting of alternative medicine, vitamins, a botanical and a homeopathic compound) .
24. The method of claim 5:. used to quantify the cognitive impairment associated with excessive exposure to radiation.
25. The method of claim 24: wherein said radiation comprises electric shock.
26. The method of claim 24: wherein said radiation comprises sunlight.
27. The method of claim 24: wherein said radiation comprises ambient electromagnetic radiation due to an electromagnetic device or structure (e.g. , cellular telephone, high tension power cable)
28. The method of claim 5: used to quantify the cognitive impairment associated with an insult.
29. The method of claim 28: wherein said insult is selected from the group consisting of a burn, heat stroke, heat exhaustion, and excess exposure to cold (e.g. , frost-nip, frostbite, hypothermia, exposure, immersion, chilblains, pernio) .
30. The method of claim 28: wherein said insult comprises an environmental insult.
31. The method of claim 30: wherein said environmental insult comprises an airborne particulate (mold, dust, etc..) .
32. A system using computer readable, tangible Memory to evaluate the cognitive performance of a person, said system comprising: a. Testing Memory on computer readable, tangible media, said Testing Memory storing cognitive dysfunction testing protocols, b. Response Memory on computer readable, tangible media, said Response Memory able to receive and store user responses to said neurological pathology testing protocols, and c. Statistical Memory on computer readable, tangible media, said Statistical Memory storing user response analysis software.
33. The method of claim 32: said Response Memory comprising a "baseline" which is not the results of said user, whereby said user response analysis software can compare (i) the cognitive function testing protocol results for said user to (ii) said baseline result.
34. The method of claim 32: said Response Memory comprising said user's cognitive pathology testing protocol results taken on at least two different times, and wherein said user response analysis software can compare said results.
35. The method of claim 34: wherein said data structure comprises responses for said user taken on at least two different times, whereby said user response analysis software can thereby compare for said user, responses of said user at a plurality of times.
36. The method of claim 35: wherein said user response analysis software calculates a reliable change index.
37. The method of claim 36: wherein said Memory is communicable to a communications device, whereby said user's cognitive dysfunction testing protocol responses may be communicated over said communication network.
38. The method of claim 37: wherein said communication network consists essentially of the Internet.
39. The method of claim 38: wherein said communication network consists essentially of a wireless telephone network.
40. The method of claim 36: used to quantify the cognitive impairment associated with motion sickness.
41. The method of claim 36: used to quantify the cognitive impairment associated with an insult selected from the group consisting of near drowning, decompression sickness (e.g. , Caisson Disease, gas embolism) and high-altitude sickness (e.g. , acute mountain sickness, high altitude pulmonary edema, high altitude cerebral edema, Soroche, Puna, aroe) .
42. The method of claim 36: used to quantify the cognitive impairment associated with non-drug medical intervention.
43. The method of claim 42: wherein said non-drug medical intervention comprises ultra-sound treatment.
44. The method of claim 42: wherein said non-drug medical intervention comprises electro-convulsion therapy.
45. The method of claim 42: wherein said non-drug medical intervention comprises radiation therapy.
46. The method of claim 42: wherein said non-drug medical intervention comprises tissue transplant.
47. The method of claim 46: wherein said tissue comprises stem cells.
48. The method of claim 46: wherein said tissue comprises at least part of an anatomical organ.
49. The method of claim 46: wherein said tissue comprises fetal tissue.
50. The method of claim 46: wherein said tissue consists essentially of genetic material.
51. The method of claim 42: wherein said non-drug medical intervention comprises nuclear medicine.
52. The method of claim 42: wherein said non-drug medical intervention comprises at least one medical scan (e.g., CT scan, Magnetic Resonance Imaging and CAT scan) .
53. The method of claim 42: wherein said non-drug medical intervention comprises at least one vaccine component.
54. The method of claim 42: wherein said non-drug medical intervention is selected from the group consisting of alternative medicine, vitamins, a botanical and a homeopathic compound) .
55. The method of claim 36: used to quantify the cognitive impairment
5δ associated with excessive exposure to radiation.
56. The method of claim 55: wherein said radiation comprises electric shock.
57. The method of claim 55: wherein said radiation comprises sunlight.
58. The method of claim 55: wherein said radiation comprises ambient electromagnetic radiation due to an electromagnetic device or structure (e.g. , cellular telephone, high tension power cable)
59. The method of claim 36: used to quantify the cognitive impairment associated with an insult.
60. The method of claim 59: wherein said insult is selected from the group consisting of a burn, heat stroke, heat exhaustion, and excess exposure to cold (e.g. , frost-nip, frostbite, hypothermia, exposure, immersion, chilblains, pernio) .
61. The method of claim 59: wherein said insult comprises an environmental insult .
62. The method of claim 61: wherein said environmental insult comprises an airborne particulate (mold, dust, etc.) .
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53454500A | 2000-03-27 | 2000-03-27 | |
| US09534545 | 2000-03-27 | ||
| PCT/US2001/002189 WO2001072217A1 (en) | 2000-03-27 | 2001-01-23 | Measuring cognitive impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001231083A1 true AU2001231083A1 (en) | 2001-10-08 |
Family
ID=24130525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001231083A Abandoned AU2001231083A1 (en) | 2000-03-27 | 2001-01-23 | Measuring cognitive impairment |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1139268A2 (en) |
| JP (1) | JP2002078699A (en) |
| KR (1) | KR20020092399A (en) |
| AU (1) | AU2001231083A1 (en) |
| CA (1) | CA2403751A1 (en) |
| IL (1) | IL151897A0 (en) |
| WO (1) | WO2001072217A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE380509T1 (en) | 1997-10-27 | 2007-12-15 | St Francis Medical Tech Inc | SPINE DISTRACTION IMPLANT |
| US7837472B1 (en) | 2001-12-27 | 2010-11-23 | The United States Of America As Represented By The Secretary Of The Army | Neurocognitive and psychomotor performance assessment and rehabilitation system |
| US8927546B2 (en) | 2006-02-28 | 2015-01-06 | Dart Neuroscience (Cayman) Ltd. | Therapeutic piperazines |
| US8202095B2 (en) | 2007-12-14 | 2012-06-19 | Medical Care Corporation | Cognitive function index |
| WO2009078856A1 (en) * | 2007-12-14 | 2009-06-25 | Medical Care Corporation | Cognitive function index |
| US20110251468A1 (en) * | 2010-04-07 | 2011-10-13 | Ivan Osorio | Responsiveness testing of a patient having brain state changes |
| US8412664B2 (en) | 2008-03-14 | 2013-04-02 | Medical Care Corporation | Non-natural pattern identification for cognitive assessment |
| BRPI0823183B8 (en) * | 2008-10-31 | 2021-06-22 | Fundacio Inst Guttmann | computer-implemented method and system to optimize predictions for personalized interventions for a given user in processes whose substrate is neuronal plasticity. |
| KR101244818B1 (en) * | 2011-03-30 | 2013-03-18 | 계명대학교 산학협력단 | Cognitive Impairment assessment service method and system based on on-line |
| US9451916B2 (en) | 2011-08-02 | 2016-09-27 | Sway Medical Llc | System and method for assessing postural sway and human motion |
| US10213149B2 (en) | 2014-05-08 | 2019-02-26 | Medical Care Corporation | Systems and methods for assessing human cognition, including a quantitative approach to assessing executive function |
| CN106108921A (en) * | 2016-08-19 | 2016-11-16 | 北京中盛凯新科技发展有限公司 | A kind of psychosoma assessment and nursing and interfering system |
| CN117796811B (en) * | 2024-02-29 | 2024-06-18 | 中国人民解放军总医院第一医学中心 | Assessment method and system for cognitive function in low-oxygen environment |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4770636A (en) * | 1987-04-10 | 1988-09-13 | Albert Einstein College Of Medicine Of Yeshiva University | Cognometer |
| US5230629A (en) * | 1991-03-01 | 1993-07-27 | Albert Einstein College Of Medicine Of Yeshiva University | Device and method for assessing cognitive speed |
| US5659741A (en) * | 1995-03-29 | 1997-08-19 | Stuart S. Bowie | Computer system and method for storing medical histories using a carrying size card |
| US6113538A (en) * | 1997-04-02 | 2000-09-05 | Bowles-Langley Technology, Inc. | Alertness tester |
-
2001
- 2001-01-23 WO PCT/US2001/002189 patent/WO2001072217A1/en not_active Ceased
- 2001-01-23 IL IL15189701A patent/IL151897A0/en unknown
- 2001-01-23 KR KR1020027012658A patent/KR20020092399A/en not_active Withdrawn
- 2001-01-23 CA CA002403751A patent/CA2403751A1/en not_active Abandoned
- 2001-01-23 AU AU2001231083A patent/AU2001231083A1/en not_active Abandoned
- 2001-03-27 JP JP2001089710A patent/JP2002078699A/en active Pending
- 2001-03-27 EP EP01302854A patent/EP1139268A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1139268A2 (en) | 2001-10-04 |
| CA2403751A1 (en) | 2001-10-04 |
| IL151897A0 (en) | 2003-04-10 |
| KR20020092399A (en) | 2002-12-11 |
| JP2002078699A (en) | 2002-03-19 |
| WO2001072217A1 (en) | 2001-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6964638B2 (en) | Measuring cognitive impairment | |
| US7087015B1 (en) | Neurological pathology diagnostic apparatus and methods | |
| ES2237801T3 (en) | INFORMATIZED DIAGNOSTIC ADVICE AND MEDICAL TREATMENT SYSTEM INCLUDING NETWORK ACCESS. | |
| US8412664B2 (en) | Non-natural pattern identification for cognitive assessment | |
| US7953613B2 (en) | Health maintenance system | |
| EP1139268A2 (en) | Measuring cognitive impairment due to incidental or intentional exposure to neurotoxic elements | |
| CN108198603A (en) | A kind of nutrition dietary based on personal physical examination information recommends method | |
| WO2008019040A2 (en) | Multimedia system and process for medical, safety and health improvements | |
| Barbier et al. | Outcome evaluation of the hand and wrist according to the International Classification of Functioning, Disability, and Health | |
| Shafiei et al. | An Integrated Electroencephalography and Eye-Tracking Analysis Using eXtreme Gradient Boosting for Mental Workload Evaluation in Surgery | |
| Ledesma et al. | The shape of health: A comparison of five alternative ways of visualizing personal health and wellbeing | |
| Gutiérrez et al. | Detection of malingering using forced-choice techniques | |
| Lang et al. | Dimensionality of the perceived self: the Tennessee Self Concept Scale | |
| EP1122678A2 (en) | Measuring pharmaceutical cognitive impairment | |
| Locsin | Development of an instrument to measure technological caring in nursing | |
| Tait | Psychological medicine in general practice | |
| Ali | Develop health monitoring and management system to track health condition and nutrient balance for school students | |
| KR20220071337A (en) | Program recording medium for providing health care services using personalized self-content | |
| Rabipour et al. | 31 Using Digital Technology for Cognitive Assessment and Enhancement in Older Adults | |
| BHATIA | Medical informatics | |
| Wohlfahrt-Laymann | CogniDecline: tracking mobile interaction for cognitive assessment | |
| Clarence | The role of fear in the length, process and cost of pre-diagnostic illness behaviour in panic disorder patients | |
| Kaplan et al. | What is well-being | |
| Hall | How adopting stereotypical roles may impact sexual risk behavior among young African American college women | |
| Marshall et al. | 11. Perceived Efficacy in Patient-Physician Interactions |